Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Drops By 88.5%

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a large drop in short interest in the month of July. As of July 15th, there was short interest totalling 52,300 shares, a drop of 88.5% from the June 30th total of 453,500 shares. Currently, 1.6% of the company’s shares are sold short. Based on an average daily volume of 40,700 shares, the days-to-cover ratio is currently 1.3 days.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Jonestrading assumed coverage on TriSalus Life Sciences in a report on Friday, May 10th. They issued a “buy” rating and a $16.00 price target on the stock. Canaccord Genuity Group assumed coverage on TriSalus Life Sciences in a report on Thursday, May 30th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $12.00 price target on shares of TriSalus Life Sciences in a report on Thursday, June 27th.

TriSalus Life Sciences Stock Down 0.9 %

Shares of TriSalus Life Sciences stock traded down $0.05 during trading on Thursday, reaching $5.62. The company’s stock had a trading volume of 6,173 shares, compared to its average volume of 35,243. TriSalus Life Sciences has a 1-year low of $3.32 and a 1-year high of $16.24. The company has a 50-day simple moving average of $6.50 and a two-hundred day simple moving average of $8.42.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.54) earnings per share for the quarter. The firm had revenue of $6.46 million during the quarter.

Institutional Trading of TriSalus Life Sciences

A hedge fund recently bought a new stake in TriSalus Life Sciences stock. Tyche Wealth Partners LLC purchased a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 26,664 shares of the company’s stock, valued at approximately $225,000. Tyche Wealth Partners LLC owned 0.10% of TriSalus Life Sciences as of its most recent filing with the Securities and Exchange Commission. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.